Research study leader Dr. Alexander Tenenbaum from Chaim Sheba Medical Center in Tel-Hashomer said “Our study has shown that bezafibrate can reduce the incidence of type 2 diabetes with a magnitude of benefit even better than other medications - 41 percent reduction during about 6 years. Moreover, bezafibrate also delayed the onset of diabetes by about 2 years.”
“It seems logical,” Tenenbaum added, that combining bezafibrate with other drugs, such as statins and metformin, might achieve even better results.
Bezafibrate lowers harmful triglycerides and raises “good” HDL-cholesterol and also reduces blood sugar levels.
The current study, Tenenbaum told Reuters Health, “reinforces the argument that management of atherogenic dyslipidemia in patients with obesity, metabolic syndrome and/or type 2 diabetes should be focused not just on LDL cholesterol, but on triglycerides and HDL cholesterol as well.”